Innovative medicine CSI ETF (517110) rose over 2.3%, Tiger Medicine rose more than 7%

Tiger Pharmaceutical rose more than 7%, and Midi, Fosun Pharmaceutical and other many rose.Innovative medicines in the Shanghai and Shenzhen ETFs (517110) rose more than 2.3%, and the turnover exceeded 3.8 million yuan.

Shen Wanhongyuan said that the domestic innovative drug industry is still in the early stages of development. Under the catalysis of the payment end, supply side, and demand side, the industry's high prosperity continues.From the perspective of space dimension, from 2020 to 2030, the size of the Chinese pharmaceutical market is expected to increase from 1.6 trillion to 3.5 trillion.In 2020, the share of Chinese innovation medicines is 7%, compared with the 70%proportion of American innovative medicines, the gap is very large. It is estimated that by 2030, the share of China's innovative drugs will increase to 70%to reach more than 2 trillion yuan.Market size.The innovative pharmaceutical industry can be said to be an industry with unlimited demand and high ceiling.Breeding huge investment opportunities.

- END -